S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead
S&P 500   4,981.80
DOW   38,612.24
QQQ   425.61
Palo Alto Networks, Keysight fall; Garmin, Toll Brothers rise, Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Palo Alto Networks aims at cyber security leadership
Spotify sounding better to analysts as company tunes into profits
Is Gold Really Boring? (Ad)
3 Reasons the Capital One-Discover merger is a big deal
How major US stock indexes fared Wednesday, 2/21/2024
Is Gold Really Boring? (Ad)
Germany says Europe's largest economy is in 'troubled waters' and cuts its growth forecast
Range-bound Home Depot stock still is, lower prices ahead

Best Penny Stocks Under 25 Cents Right Now

It can be difficult to find a deal in the stock market regardless of current market conditions. For the last decade, stocks have traded well above historical average P/E ratios. Fortunately there are still a handful of undervalued stocks in corners of the market that most investors ignore. These penny stocks all have a super-low share price of $0.25 or less and are sorted by average trading volume in dollars. These companies are considered the most actively-traded stocks priced under $0.25.

Canoo stock logo

#1 - Canoo

NYSE:GOEV
Stock Price:
$0.13
P/E Ratio:
-0.16
Market Cap:
$123.24 million
Average Trading Volume:
67.65 million shares
Consensus Rating:
Buy (4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.33 (1,758.5% Upside)
Canoo Inc., a mobility technology company, designs, engineers, develops, and manufactures electric vehicles for commercial and consumer markets in the United States. The company offers lifestyle delivery vehicles, lifestyle vehicles, multi-purpose delivery vehicles, and pickups. It also provides multi-purpose platform architecture is a self-contained, fully functional rolling chassis that directly houses the critical components for operation of an EV. Canoo Inc. was founded in 2017 and is headquartered in Torrance, California.
Sientra stock logo

#2 - Sientra

NASDAQ:SIEN
Stock Price:
$0.17 (-$0.04)
P/E Ratio:
-0.03
Market Cap:
$2.56 million
Average Trading Volume:
7.04 million shares
Consensus Rating:
Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$7.50 (4,210.3% Upside)
Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products in the United States and internationally. It offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra Round, Sientra Teardrop, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names. The company also provides fat transfer systems; body contouring products; facial and nasal implants; saline filled sizers. It serves to hospitals, surgery centers, plastic surgeons, dermatologists, and other specialties. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Irvine, California.
Avenue Therapeutics stock logo

#3 - Avenue Therapeutics

NASDAQ:ATXI
Stock Price:
$0.15
P/E Ratio:
-0.25
Market Cap:
$1.98 million
Average Trading Volume:
8.15 million shares
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$32.00 (21,319.0% Upside)
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of rare and neurologic diseases in the United States. Its lead product candidate includes AJ201, which in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous (IV) Tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. Avenue Therapeutics, Inc. was incorporated in 2015 and is based in Tampa, Florida.
Tritium DCFC stock logo

#4 - Tritium DCFC

NASDAQ:DCFC
Stock Price:
$0.14
Market Cap:
$23.67 million
Average Trading Volume:
7.93 million shares
Consensus Rating:
Hold (0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.00 (1,364.1% Upside)
Tritium DCFC Limited designs, manufactures, and supplies direct current chargers for electric vehicles in Australia and internationally. The company's charging station hardware portfolio includes various standalone chargers and distributed chargers. Its service and maintenance portfolio includes warranties, service level agreements, and sales of spare parts. The company operates a service management software platform; and provides high-power charging sessions. It serves charge point operators, automakers, electric vehicle fleets, and fuel stations, as well as retail and utility sectors. Tritium DCFC Limited was founded in 2001 and is based in Murarrie, Australia.
AgriFORCE Growing Systems stock logo

#5 - AgriFORCE Growing Systems

NASDAQ:AGRI
Stock Price:
$0.23 (-$0.04)
P/E Ratio:
-0.01
Market Cap:
$328,000.00
Average Trading Volume:
4.22 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$100.00 (42,836.9% Upside)
AgriFORCE Growing Systems Ltd., an agriculture-focused technology company, focuses on the development and commercialization of plant-based ingredients and products that deliver healthier and nutritious solutions. The company operates in two divisions, AgriFORCE Solutions and AgriFORCE Brands. It also offers management advisory services and holds intellectual property, as well as engages in the real estate holding and development activities. The company was formerly known as Canivate Growing Systems Ltd. and changed its name to AgriFORCE Growing Systems Ltd. in November 2019. AgriFORCE Growing Systems Ltd. was incorporated in 2017 and is headquartered in Vancouver, Canada.
Charge Enterprises stock logo

#6 - Charge Enterprises

NASDAQ:CRGE
Stock Price:
$0.08 (-$0.01)
P/E Ratio:
-0.40
Market Cap:
$18.28 million
Average Trading Volume:
11.93 million shares
Consensus Rating:
Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.50 (5,525.0% Upside)
Charge Enterprises Inc. operates as an electrical, broadband, and electric vehicle (EV) charging infrastructure company. The company provides clients with end-to-end project management services, including advising, designing, engineering, acquiring and installing equipment, monitoring, servicing, and maintenance. It operates in two segments, Infrastructure and Telecommunications. The Infrastructure segment offers broadband and wireless, electrical contracting, electric vehicle charging, and fleet services. The Telecommunications segment provides internet-protocol-based and time-division multiplexing access for transport of long-distance voice and data minutes; domestic switching and related peripheral equipment services, and carrier-grade routers and switches for internet and circuit-based services, as well as connection of voice calls and data services. The company was formerly known as TransWorld Holdings Inc and changed its name to Charge Enterprises, Inc. in January 2021. Charge Enterprises, Inc. was incorporated in 2003 and is based in New York, New York.
Kintara Therapeutics stock logo

#7 - Kintara Therapeutics

NASDAQ:KTRA
Stock Price:
$0.09
P/E Ratio:
-0.02
Market Cap:
$330,000.00
Average Trading Volume:
9.83 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
CISO Global stock logo

#8 - CISO Global

NASDAQ:CISO
Stock Price:
$0.13 (-$0.02)
Market Cap:
$26.49 million
Average Trading Volume:
6.18 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
CISO Global Inc. operates as a cybersecurity and compliance company in the United States, Chile, and internationally. Its cybersecurity services include security managed, cybersecurity consulting, compliance auditing, vulnerability assessment, penetration testing, disaster recovery, data backup, and cybersecurity training services. The company was formerly known as Cerberus Cyber Sentinel Corporation and changed its name to CISO Global Inc. in May 2023. CISO Global Inc. was founded in 2015 and is headquartered in Scottsdale, Arizona.
Pineapple Energy stock logo

#9 - Pineapple Energy

NASDAQ:PEGY
Stock Price:
$0.08 (-$0.01)
P/E Ratio:
-0.06
Market Cap:
$900,000.00
Average Trading Volume:
8.21 million shares
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.00 (4,736.8% Upside)
Pineapple Energy Inc. engages in the sale, design, and installation of photovoltaic solar energy systems and battery storage systems in the United States. Its brand portfolio includes SUNation, Hawaii Energy Connection, E-Gear, Sungevity, and Horizon Solar Power. The company develops and manufactures energy management software and hardware, such as energy management control devices on solar systems that are paired with batteries. It primarily serves residential homeowners, as well as commercial owners, other municipal customers, energy services companies, and other utilities. Pineapple Energy Inc. was founded in 1969 and is based in Minnetonka, Minnesota.
LumiraDx stock logo

#10 - LumiraDx

NASDAQ:LMDX
Stock Price:
$0.01
P/E Ratio:
-0.01
Market Cap:
$3.03 million
Average Trading Volume:
56.75 million shares
Consensus Rating:
Moderate Buy (1 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1.45 (15,163.2% Upside)
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.
Sonoma Pharmaceuticals stock logo

#11 - Sonoma Pharmaceuticals

NASDAQ:SNOA
Stock Price:
$0.15
P/E Ratio:
-0.16
Market Cap:
$2.47 million
Average Trading Volume:
3.40 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.25 (2,004.9% Upside)
Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.
Sintx Technologies stock logo

#12 - Sintx Technologies

NASDAQ:SINT
Stock Price:
$0.15
Market Cap:
$795,000.00
Average Trading Volume:
3.28 million shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications in the United States. It provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.
Airspan Networks stock logo

#13 - Airspan Networks

NYSE:MIMO
Stock Price:
$0.13 (-$0.01)
P/E Ratio:
-0.17
Market Cap:
$9.92 million
Average Trading Volume:
3.55 million shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
Airspan Networks Holdings Inc. designs and produces wireless network equipment for 4G and 5G networks for mainstream public telecommunications service providers and private network implementations. It offers a range of 4G and 5G network build and network densification products with a portfolio of software and hardware tools for indoor and outdoor, compact femto, pico, micro, and macro base stations, as well as fixed wireless access and backhaul solutions portfolio for point-to-point and point-to-multipoint applications. The company also provides software defined radios, broadband access products, and network management software. It serves mobile communications service providers, large enterprises, military communications integrators, and internet service providers. Airspan Networks Holdings Inc. is headquartered in Boca Raton, Florida.
BIOLASE stock logo

#14 - BIOLASE

NASDAQ:BIOL
Stock Price:
$0.14 (-$0.01)
P/E Ratio:
0.00
Market Cap:
$630,000.00
Average Trading Volume:
2.90 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$77.00 (53,633.4% Upside)
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, therapy pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.
Invitae stock logo

#15 - Invitae

NYSE:NVTA
Stock Price:
$0.02
P/E Ratio:
0.00
Market Cap:
$4.49 million
Average Trading Volume:
23.72 million shares
Consensus Rating:
Strong Sell (0 Buy Ratings, 0 Hold Ratings, 3 Sell Ratings)
Consensus Price Target:
$1.00 (5,852.4% Upside)
Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.
Better Therapeutics stock logo

#16 - Better Therapeutics

NASDAQ:BTTX
Stock Price:
$0.16 (-$0.01)
P/E Ratio:
-0.14
Market Cap:
$8.46 million
Average Trading Volume:
2.32 million shares
Consensus Rating:
Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$6.00 (3,574.2% Upside)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
Northern Dynasty Minerals stock logo

#17 - Northern Dynasty Minerals

NYSEAMERICAN:NAK
Stock Price:
$0.24
P/E Ratio:
-6.00
Market Cap:
$131.01 million
Average Trading Volume:
1.56 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$0.80 (233.3% Upside)
Northern Dynasty Minerals Ltd. engages in the exploration of mineral properties in the United States. It holds a 100% interest in the Pebble Copper-Gold-Molybdenum-Silver-Rhenium project comprising 1,840 mineral claims that covers an area of approximately 274 square miles located in southwest Alaska, the United States. The company was formerly known as Northern Dynasty Explorations Ltd. and changed its name to Northern Dynasty Minerals Ltd. in October 1997. Northern Dynasty Minerals Ltd. was incorporated in 1983 and is headquartered in Vancouver, Canada.
WiSA Technologies stock logo

#18 - WiSA Technologies

NASDAQ:WISA
Stock Price:
$0.04 (-$0.01)
Market Cap:
$850,000.00
Average Trading Volume:
8.33 million shares
Consensus Rating:
Hold (0 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$6.00 (14,084.4% Upside)
WiSA Technologies, Inc. develops, manufactures, and sells audio wireless technology for smart devices and next-generation home entertainment systems in the United States and Europe. The company offers wireless modules. It serves primarily to consumer electronics companies. The company was formerly known as Summit Wireless Technologies, Inc. and changed its name to WiSA Technologies Inc. in March 2022. WiSA Technologies, Inc. was incorporated in 2010 and is headquartered in Beaverton, Oregon.
Sunshine Biopharma stock logo

#19 - Sunshine Biopharma

NASDAQ:SBFM
Stock Price:
$0.06
P/E Ratio:
-0.04
Market Cap:
$1.57 million
Average Trading Volume:
4.29 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$2.60 (4,155.3% Upside)
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.
KULR Technology Group stock logo

#20 - KULR Technology Group

NYSEAMERICAN:KULR
Stock Price:
0.14 (-0.03)
P/E Ratio:
-0.70
Market Cap:
$17.91 million
Average Trading Volume:
1.80 million shares
Consensus Rating:
Buy (2 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
N/A
KULR Technology Group, Inc., through its subsidiary, KULR Technology Corporation, develops and commercializes thermal management technologies for batteries, electronics, and other components applications in the United States. It provides lithium-ion battery thermal runaway shields; fiber thermal interface materials; phase change material heatsinks; internal short circuit device; KULR battery cell screening and testing automation system and tech safe case; cellcheck; and CRUX cathodes. The company's technologies are used in electric vehicles, energy storage, battery recycling transportation, cloud computing, and 5G communication devices. It sells its products for applications, such as lithium-ion battery energy storage, electric vehicles, 5G communication, cloud computer infrastructure, consumer, and industrial devices. The company was formerly known as KT High-Tech Marketing Inc. and changed its name to KULR Technology Group, Inc. in August 2018. KULR Technology Group, Inc. was founded in 2013 and is based in San Diego, California.
Nutex Health stock logo

#21 - Nutex Health

NASDAQ:NUTX
Stock Price:
$0.12
P/E Ratio:
-2.36
Market Cap:
$76.94 million
Average Trading Volume:
2.02 million shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1.00 (747.5% Upside)
Nutex Health Inc. operates as a network of micro-hospitals. It operates through three segments: Hospital, Population Health Management, and Real Estate. The Hospital segment develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments which offers 24/7 care. The Population Health Management segment establishes and operates independent physician associations; and offers a cloud-based platform for healthcare organizations to provide value-based care and population health management. The Real Estate segment leases land and hospital building. It also provides healthcare and facility management services; and healthcare billing, coding, and collection services. In addition, the company offers healthcare services, including emergency room care, inpatient care, and behavioral health, as well as onsite imaging, such as CT scan, X-ray, MRI, ultrasound, etc.; certified and accredited laboratories; and onsite inpatient pharmacies. The company was founded in 2011 and is based in Houston, Texas.
TRACON Pharmaceuticals stock logo

#22 - TRACON Pharmaceuticals

NASDAQ:TCON
Stock Price:
$0.18
P/E Ratio:
-0.31
Market Cap:
$5.80 million
Average Trading Volume:
968,632 shares
Consensus Rating:
Moderate Buy (2 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$4.33 (2,292.8% Upside)
TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.
Matinas BioPharma stock logo

#23 - Matinas BioPharma

NYSEAMERICAN:MTNB
Stock Price:
$0.23 (-$0.01)
P/E Ratio:
-2.12
Market Cap:
$51.90 million
Average Trading Volume:
721,213 shares
Consensus Rating:
Buy (1 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$3.00 (1,184.8% Upside)
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
Edgio stock logo

#24 - Edgio

NASDAQ:EGIO
Stock Price:
$0.23
P/E Ratio:
-0.35
Market Cap:
$52.24 million
Average Trading Volume:
736,582 shares
Consensus Rating:
Hold (1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$1.08 (381.5% Upside)
Edgio, Inc. provides edge-enabled software solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company operates private global networks with distributed computing resources and extensive connectivity to last-mile broadband network providers; offers live and on-demand video delivery services; and provides platform, media, and application solutions. It also offers cloud security, edge compute, origin storage, and support services. In addition, the company provides content delivery, video content management, and streaming services, performance services for website and web application and security; professional services, cloud storage, and edge computing services. The company was formerly known as Limelight Networks, Inc. and changed its name to Edgio, Inc. in June 2022. Edgio, Inc. was founded in 2001 and is headquartered in Phoenix, Arizona.
22nd Century Group stock logo

#25 - 22nd Century Group

NASDAQ:XXII
Stock Price:
$0.16
P/E Ratio:
-0.02
Market Cap:
$4.85 million
Average Trading Volume:
1.05 million shares
Consensus Rating:
Moderate Buy (2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings)
Consensus Price Target:
$19.17 (12,131.4% Upside)
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.

More Stock Ideas from MarketBeat